^
    Back
    Association details:
    Biomarker:EML4-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Am J Case Rep
    Title:

    Neoadjuvant Lorlatinib Induces Pathological Complete Response in Advanced ALK-Positive Lung Cancer: A Case Report

    Published date:
    11/07/2023
    Excerpt:
    A 54-year-old man was diagnosed with stage IIIB (pT1N3M0) upper right lung adenocarcinoma carrying the EML4-ALK fusion gene….the patient received 1 cycle of chemotherapy with paclitaxel in combination with nedaplatin and subsequently received maintenance treatment involving lorlatinib. Two months later, clinical evaluations revealed progressive reduction of the lesions, especially the reduced size of the mediastinal lymph nodes.
    DOI:
    10.12659/AJCR.942150